Vitronectin receptor antagonist pharmaceuticals
US7332149B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 21, 2000 |
| Grant date | Feb 19, 2008 |
| Priority date | — |
| Expiry date | Jun 9, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K5/06191
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention describes novel compounds of the formula:(Q)d—Ln—Ch,useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention also provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention also provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.